Mycenax Biotech Inc. (TPEX:4726)

Market Cap	6.18B -27.8%
Revenue (ttm)	740.24M +8.2%
Net Income	-448.63M
EPS	-2.17
Shares Out	207.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	534,103
Average Volume	248,169
Open	30.35
Previous Close	30.35
Day's Range	29.65 - 30.45
52-Week Range	29.30 - 41.75
Beta	0.59
RSI	35.72
Earnings Date	Feb 26, 2026

About Mycenax Biotech

Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug conjugates, cell and gene therapy, and exosomes products and services. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 387
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4726

Financial Performance

In 2025, Mycenax Biotech's revenue was 740.24 million, an increase of 8.23% compared to the previous year's 683.92 million. Losses were -448.63 million, -3.96% less than in 2024.